Mechanism of interaction between the transactivation domain of N-myc and the DNA-binding surface of TFIIIC5
Nucleic Acids Research · 2026
DOI: 10.1093/nar/gkag181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Eoin Leen und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom. Hauptthemen laut MEDLINE: Transcription Factors, TFIII, Proto-Oncogene Proteins c-myc, DNA. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Mildred Scheel Junior Research Center Program, Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
N-myc is a transcription factor, a powerful driver of cellular growth and an important oncoprotein. N-myc interacts with many factors, including the RNA Polymerase III assembly factor, TFIIIC, a six-subunit complex that is essential for the transcription of small, structured RNA. TFIIIC and N-myc mutually restrict each other’s chromatin association, and their complex contributes to quality control in mRNA transcription. We previously demonstrated that the intrinsically disordered transactivation domain of N-myc interacts directly with a sub-complex of TFIIIC, τA. Structural studies by others show that DNA binding of τA is largely mediated by TFIIIC3, leaving open the role of the DNA-binding domain of TFIIIC5. Here, we demonstrate that this domain is a binding site for two regions in the transactivation domain of N-myc, through an integrated approach combining NMR spectroscopy, hydrogen–deuterium exchange mass spectrometry, and interaction assays (pull-downs, ITC, fluorescence polarization, and co-immunoprecipitation). AlphaFold modelling predicts with high-confidence a binding mode for the higher affinity N-myc motif that overlaps with the predicted intramolecular binding site of the C-terminal acidic plug of TFIIIC5, removal of which enhances the binding of N-myc. This model elucidates how the N-myc:TFIIIC5 interaction competes with DNA and other interactions, providing a basis for their mutual regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom.
- Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom.
- Theodor Boveri Institute, Department of Biochemistry and Molecular Biology, Biocenter, University of Würzburg, 97074 Würzburg, Germany.
- Comprehensive Cancer Center Mainfranken, 97080 Würzburg, Germany.
- Mildred Scheel Early Career Center, University Hospital Würzburg, 97080 Würzburg, Germany.
ORCID-Profile: Eoin Leen, Gabriele Büchel, Richard Bayliss
Förderung
- Medical Research Council
- Mildred Scheel Junior Research Center Program
- Biotechnology and Biological Sciences Research Council
- Wellcome Trust
- Royal Society
- MRC World Class Labs
- University of Leeds
- Oxford University Press
Zitieren
APA
Leen, E., Yeoh, S., Sahak, E., Mitchell, E., Wildsmith, G., Batchelor, M., Calabrese, A. N., Büchel, G., & Bayliss, R. (2026). Mechanism of interaction between the transactivation domain of N-myc and the DNA-binding surface of TFIIIC5. Nucleic Acids Research. https://doi.org/10.1093/nar/gkag181
Vancouver
Leen E, Yeoh S, Sahak E, Mitchell E, Wildsmith G, Batchelor M, et al. Mechanism of interaction between the transactivation domain of N-myc and the DNA-binding surface of TFIIIC5. Nucleic Acids Research. 2026. doi:10.1093/nar/gkag181
BibTeX
@article{Leen2026,
author = {Leen, Eoin and Yeoh, Sharon and Sahak, Eka and Mitchell, Ellie and Wildsmith, Gemma and Batchelor, Matthew and Calabrese, Antonio N and Büchel, Gabriele and Bayliss, Richard},
title = {Mechanism of interaction between the transactivation domain of N-myc and the DNA-binding surface of TFIIIC5},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkag181}
}
EUVIMED